Search Results - "Kowaleski, Brenda"

Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable? by SEOW, Hsien-Yeang, WHELAN, Patrick, LEVINE, Mark N, COWAN, Kathryn, LYSAKOWSKI, Barbara, KOWALESKI, Brenda, SNIDER, Anne, XU, Rebecca Y, ARNOLD, Andrew

“…Many oncology clinical trials departments (CTDs) are in serious fiscal deficit and their sustainability is in jeopardy. This study investigates whether the…”
Get full text

What constitutes a "clinical trial"?: a survey of oncology professionals by Wright, James R, Kowaleski, Brenda, Sussman, Jonathan

“…What constitutes a "clinical trial" is inconsistently defined in the medical literature. With an initiative by Cancer Care Ontario (CCO) to report…”
Get full text

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials by Mukherjee, Som D., Coombes, Megan E., Levine, Mitch, Cosby, Jarold, Kowaleski, Brenda, Arnold, Andrew

“…Summary Background In early phase oncology trials, novel targeted therapies are increasingly being tested in combination with traditional agents creating…”
Get full text

Ontario protocol assessment level: clinical trial complexity rating tool for workload planning in oncology clinical trials by Smuck, Bobbi, Bettello, Phyllis, Berghout, Koralee, Hanna, Tracie, Kowaleski, Brenda, Phippard, Lynda, Au, Diana, Friel, Kay

“…The Ontario Institute for Cancer Research supported the creation of a working group with the objective of developing a standard rating scale to evaluate…”
Get full text

The arotinoids: early clinical experience and discussion of future development by Arnold, A, Kowaleski, B, Tozer, R, Hirte, H

“…There has been great interest in the use of drugs attempting to modify the properties of malignant cells without necessarily destroying them. The family of…”
Get more information

The arotinoids: early clinical experience and discussion of future development by Arnold, A, Kowaleski, B, Tozer, R, Hirte, H

“…There has been great interest in the use of drugs attempting to modify the properties of malignant cells without necessarily destroying them. The family of…”
Get more information